中国肺癌杂志最新文献

{"title":"[Expert Consensus on Shared Decision-making in the Diagnosis and Treatment \u2029of Ground-glass Opacity-featured Lung Adenocarcinoma].","authors":"Xiaogang Zhao, Jie Cai, Deping Zhao, Chang Chen","doi":"10.3779/j.issn.1009-3419.2026.106.06","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.06","url":null,"abstract":"<p><p>With the popularization of low-dose computed tomography (LDCT) screening, the detection rate of ground-glass opacity (GGO) has been continuously increasing. Ground-glass opacity-featured lung adenocarcinoma is mostly characterized by indolent biological behavior and favorable prognosis. However, its progression is uncertain and recommendations vary among guidelines. This places clinicians in a dilemma between timely intervention and avoiding overdiagnosis and overtreatment, while patients often suffer from follow-up anxiety and decision-making confusion. To standardize the whole-process management on an evidence-based basis and fully incorporate patient values, this expert consensus systematically reviews the entire procedure of GGO diagnosis and treatment, establishes shared decision-making between doctors and patients as the core principle, and emphasizes formulating management strategies by integrating patient values, life goals and risk preferences. The consensus covers key components including the starting and ending ages for screening, limitations of imaging diagnosis and indications for invasive diagnosis, indications and timing of surgery, strategies for sublobar resection and lymph node management, management of multiple GGOs, non-surgical alternative therapies, reliability of intraoperative frozen-section pathology, postoperative enhanced recovery and pain management, eligible populations for adjuvant therapy, and follow-up strategies. By promoting multidisciplinary collaboration and structured communication, this consensus aims to facilitate the transformation of the diagnosis and treatment model from disease-centered to patient value-centered, improve medical quality and patient satisfaction, reduce overtreatment, and promote doctor-patient harmony.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 2","pages":"81-104"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Safety and Clinical Benefit Analysis of No-chest-tube Strategy After Uniportal Video-assisted Thoracoscopic Pulmonary Wedge Resection Based on Propensity Score Matching].","authors":"Chutong Lin, Yingze Ning, Shanwu Ma, Jizheng Tang, Liang Jin, Wei He, Huayu He, Guangliang Qiang","doi":"10.3779/j.issn.1009-3419.2026.102.04","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.04","url":null,"abstract":"<p><strong>Background: </strong>With the wide application of uniportal video-assisted thoracoscopy in the diagnosis and treatment of small pulmonary nodules, the optimization of postoperative chest tube management has become a focus of enhanced recovery after thoracic surgery. This study aimed to investigate the safety and non-inferiority of a no-drain strategy following uniportal video-assisted thoracoscopic wedge resection.</p><p><strong>Methods: </strong>A total of 203 eligible patients who underwent surgery between January 2023 and May 2025 were enrolled and allocated to the no-drain group (n=53) and the drain group (n=150). After propensity score matching (PSM), 41 well-balanced pairs were generated. Non-inferiority testing combined with Bayesian analysis was performed to assess postoperative outcomes.</p><p><strong>Results: </strong>After PSM, the no-drain group met the predefined non-inferiority criteria for the incidence of postoperative fever (19.51% vs 26.83%), pleural effusion (24.39% vs 21.95%), and the proportion of patients requiring additional analgesics (12.20% vs 9.76%), with the upper bound of the 95%CI for between-group differences not exceeding the 10% non-inferiority margin. The no-drain group demonstrated a significantly shorter median postoperative length of stay (2.00 vs 3.00 d, P<0.001) and lower visual analogue scale (VAS) scores on postoperative day 1 (P=0.0495), with non-inferiority confirmed. However, non-inferiority was not established for secondary intervention rates (primarily chest tube reinsertion, 4.88% vs 0.00%) or radiologic complications (73.17% vs 65.85%), as the upper limit of the 95%CI for the between-group differences exceeded the 10% margin. Bayesian analysis showed that the probability that the positive rate of imaging-related complications in the no-drain group was higher than that in the drain group was 77.18%, and the probability that the absolute value of the difference in positive rates between the two groups greater than 10.0% was 44.45%.</p><p><strong>Conclusions: </strong>In carefully selected low-risk patients, a no-drain strategy following uniportal thoracoscopic wedge resection may reduce postoperative pain and shorten hospital stay, while meeting non-inferiority criteria for key safety outcomes. However, non-inferiority was not demonstrated for secondary chest tube insertion or radiologic complications. Enhanced postoperative monitoring is therefore essential to ensure clinical safety.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 2","pages":"105-114"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Huangqi Guizhi Wuwu Decoction in the Treatment of Pemetrexed \u2029Intrathecal Chemotherapy-induced Neurotoxicity in NSCLC Patients \u2029with Leptomeningeal Metastases: A Randomized Controlled Trial].","authors":"Huiying Li, Xin Chen, Yu Xie, Cheng Jiang, Yongjuan Lin, Tingting Yu, Zhenyu Yin","doi":"10.3779/j.issn.1009-3419.2026.102.02","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.02","url":null,"abstract":"<p><strong>Background: </strong>Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). Although intrathecal Pemetrexed chemotherapy can effectively prolong patient survival, a high incidence of neurotoxicity has emerged as a critical factor limiting its clinical application. This study aims to investigate the efficacy and safety of Huangqi Guizhi Wuwu decoction (HGWD) in mitigating neurotoxicity induced by intrathecal Pemetrexed chemotherapy in NSCLC patients with LM.</p><p><strong>Methods: </strong>In a prospective, randomized, double-blind, controlled trial, 220 NSCLC patients with LM were enrolled and randomly assigned to either the treatment group (HGWD+intrathecal chemotherapy) or the control group (placebo+intrathecal chemotherapy), with 110 patients in each group. The incidence and grade of neurotoxicity, disease control rate (DCR), progression-free survival (PFS), overall survival (OS), quality of life, and adverse reactions were observed and compared between the two groups.</p><p><strong>Results: </strong>The incidence of neurotoxicity in the treatment group was 29.1%, significantly lower than that in the control group (51.8%)(P<0.001). The incidences of both grade 1-2 and grade 3-4 neurotoxicity were lower in the treatment group than in the control group (P<0.010). Nerve conduction studies showed that the sensory nerve action potential amplitude of the sural nerve was significantly higher in the treatment group than in the control group (P=0.012), and the conduction velocities of the median and ulnar nerves showed a trend toward improvement. The DCR was 76.4% in the treatment group, higher than 69.1% in the control group (P=0.045). Both median PFS (7.8 vs 6.1 mon, P<0.001) and median OS (10.5 vs 8.9 mon, P=0.007) were significantly prolonged in the treatment group. Improvements in quality of life and traditional Chinese medicine syndrome scores were superior in the treatment group (P<0.05). No significant difference in adverse reactions were observed.</p><p><strong>Conclusions: </strong>HGWD can significantly reduce the incidence of neurotoxicity induced by Pemetrexed intrathecal chemotherapy, improve chemotherapy tolerance and survival benefits, with a good safety profile in NSCLC patients with LM.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 2","pages":"124-130"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress on the Role and Mechanisms of PYCR1 \u2029in Tumorigenesis and Progression].","authors":"Yuqi Meng, Zhichang Yang, Haiming Feng, Haitian Li, Bin Li","doi":"10.3779/j.issn.1009-3419.2026.106.04","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.04","url":null,"abstract":"<p><p>Pyrroline-5-carboxylate reductase 1 (PYCR1) is a key enzyme in the proline biosynthesis pathway and has garnered widespread attention in the field of tumor research in recent years. Studies have shown that PYCR1 is abnormally expressed in a variety of malignant tumors. It plays a significant role in tumorigenesis and development by participating in metabolic reprogramming of tumor cells, regulating key signaling pathways, influencing the tumor microenvironment, and mediating immune evasion, among other mechanisms. This article systematically reviews the biological structure and functions of PYCR1, its expression characteristics in various tumors, and the underlying molecular mechanisms. The focus is on exploring its role in promoting the occurrence and development of different tumors, as well as its involvement in mediating chemotherapy resistance. Additionally, the research progress and clinical application prospects of PYCR1 as a potential therapeutic target are analyzed, providing a theoretical basis and research directions for the development of novel anti-tumor strategies.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 2","pages":"131-140"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of HIF-1α-expressing Cellular Subpopulations on Lymph Node Metastasis \u2029and Postoperative Recurrence in Non-small Cell Lung Cancer].","authors":"Fanghan Cao, Qianhui Chen, Liying Yang, Miaoqing Zhao, Xiaorong Sun, Ligang Xing","doi":"10.3779/j.issn.1009-3419.2026.106.05","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.05","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Non-small cell lung cancer (NSCLC) is associated with a high rate of postoperative recurrence, and conventional tumor-node-metastasis (TNM) staging does not fully reflect its biological heterogeneity. Hypoxia-inducible factor-1alpha (HIF-1α) plays a critical role in tumor progression and remodeling of the tumor immune microenvironment. However, the spatial distribution of HIF-1α and its prognostic significance in the context of different lymph node metastatic states remain unclear. This study aimed to investigate the densities of HIF-1α-expressing tumor cells, CD4+ T cells, and CD8+ T cells in the primary tumors of NSCLC patients, and to assess their associations with lymph node metastasis and postoperative recurrence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;256 formalin-fixed paraffin-embedded primary tumor specimens from NSCLC patients who underwent radical resection at Shandong First Medical University Affiliated Cancer Hospital between January 1, 2014 and December 31, 2018 were retrospectively collected. Tissue microarrays containing both tumor center (TC) and invasive margin (IM) regions were constructed and multiplex immunofluorescence staining [HIF-1α/CD4/CD8/cytokeratin (CK)/4',6-diamidino-2-phenylindole (DAPI)] were performed to quantitatively analyze the densities of HIF-1α-expressing tumor cells (HIF-1α+CK+), HIF-1α+CD4+ T cells and HIF-1α+CD8+ T cells. Mann-Whitney U tests were used to compare cellular density differences between N0 versus N1-2 groups and N1 versus N2 subgroups, while Cox proportional hazards regression models were employed to identify critical recurrence-associated factors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The study ultimately included 256 patients with stage IA-IIIB NSCLC, with a median follow-up duration of 37.05 months, during which 87 cases (34.0%) experienced recurrence. Comparative analysis revealed that in both TC and IM regions, the N1-2 group exhibited significantly higher densities of HIF-1α+CK+ cells (P values: 0.039 and &lt;0.001, respectively) and lower densities of HIF-1α+CD8+ cells (both P values: &lt;0.001) compared to the N0 group, while no statistically significant differences were observed in the densities of HIF-1α+CK+ cells, HIF-1α+CD4+ cells, or HIF-1α+CD8+ cells between N1 and N2 subgroups within either TC or IM regions (all P&gt;0.05). Multivariate Cox regression analysis showed that, among N0 patients, a low density of HIF-1α+CD8+ cells in the TC was an independent risk factor for recurrence in NSCLC patients [hazard ratio (HR)=1.998, 95%CI: 1.077-3.705, P=0.028]. In contrast, among N1 and N2 patients, the densities of HIF-1α+CK+ cells, HIF-1α+CD4+ T cells, and HIF-1α+CD8+ cells in both the TC and IM regions were not significantly associated with NSCLC recurrence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In patients with NSCLC, lymph node metastasis is closely associated with alterations in the densities of HIF-1α-related cellular subpopulations in the primary tumor. A reduced densit","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 2","pages":"115-123"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[New Landscape in the Treatment of Limited-stage Small Cell Lung Cancer: \u2029From Conventional Chemoradiotherapy to Latest Advances in Precision Medicine].","authors":"Jingwen Han, Keyao Dai, Zixi Meng, Jun Huang","doi":"10.3779/j.issn.1009-3419.2026.101.04","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.04","url":null,"abstract":"<p><p>Limited-stage small cell lung cancer (LS-SCLC) is a highly aggressive malignancy with a poor prognosis. For a long time, the standard first-line treatment has been Etoposide plus Platinum-based chemotherapy combined with concurrent thoracic radiotherapy; however, most patients still face recurrence and drug resistance. This article systematically reviews major recent advances in the field, aiming to illustrate the new paradigm shifting from conventional chemoradiotherapy toward precision-integrated therapy. Radiotherapy techniques continue to be optimized, and the value of surgery has been reaffirmed in rigorously selected early-stage patients; immunotherapy has achieved a milestone breakthrough, with the ADRIATIC trial demonstrating that consolidation therapy with Durvalumab after chemoradiotherapy significantly extends median overall survival (55.9 vs 33.4 months); meanwhile, targeted therapies based on molecular subtyping also show promise. This paper clarifies the optimized directions of multimodal treatment strategies, emphasizes the guiding significance of molecular subtyping and biomarkers in individualized therapy, with the aim of providing reference for clinical practice, offering a framework for future research, and ultimately improving the survival outcomes of LS-SCLC patients as a whole.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 2","pages":"150-158"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances in Lactate Metabolic Reprogramming in Non-small Cell Lung Cancer].","authors":"Jun Zhou, Liuling Ge, Jingting Jiang","doi":"10.3779/j.issn.1009-3419.2026.106.03","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.03","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) is characterized by high incidence and mortality, with a low five-year survival rate. Lactate metabolism plays a central role in the metabolic reprogramming of NSCLC. Beyond serving as the end-product of glycolysis, lactate accumulates in the tumor microenvironment (TME), contributing to acidification, and can also enter the tricarboxylic acid cycle to participate in energy metabolism. Moreover, the G protein-coupled receptor 81 (GPR81)/phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling axis induces the expression of immune checkpoint molecules, such as programmed death-ligand 1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), thereby suppressing the functions of T lymphocytes and natural killer cells and establishing an immunosuppressive microenvironment. Lactate further promotes epithelial-mesenchymal transition and tumor metastasis, and drives NSCLC chemoresistance and relapse via histone lactylation. Clinical studies indicate that enhanced lactate metabolism is associated with NSCLC progression and chemotherapy resistance, while targeting lactate metabolism in combination with immunotherapy exerts synergistic antitumor effects. Therefore, comprehensive inhibition of lactate metabolism together with enhancement of antitumor immunity may improve the efficacy of precision therapy in NSCLC.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 2","pages":"141-149"},"PeriodicalIF":0.0,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case Report of Successful Control of Refractory Tumor Fever \u2029in Lung Adenocarcinoma with Interleukin-6 Antibody Tocilizumab].","authors":"Ying Li, Chunhui Li, Bin Li","doi":"10.3779/j.issn.1009-3419.2026.102.01","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.01","url":null,"abstract":"<p><p>Fever is a common symptom of lung cancer, but most are induced by infection. This is the first report of a patient with lung adenocarcinoma who developed a fever of unknown origin for more than 1 month after repeat biopsy on the progression of first-line treatment in China. Comprehensive blood tests, the well-known pathogens were fully examined, and imaging studies failed to support infectious fever, connective tissue disease-related fever, drug fever, or other etiologies, leading to the diagnosis of tumor fever. While the fever remained refractory to Ibuprofen, it was successfully controlled 12 h after a single intravenous administration of Tocilizumab, with the patient maintaining a normal body temperature for 45 days, from August 21 to October 4, 2025. This case report primarily provides the practice for exploring the tumor fever.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"77-80"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese Expert Consensus on Clinical Management of Oncogene Addicted \u2029Non-small Cell Lung Cancer with Leptomeningeal Metastasis (2026 Edition)].","authors":"","doi":"10.3779/j.issn.1009-3419.2025.102.39","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.39","url":null,"abstract":"<p><p>The prognosis for non-small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is extremely poor. However, in oncogene addicted patients, the emergence of targeted therapies with high central nervous system (CNS) penetration is significantly reshaping the treatment landscape. Existing guidelines, which often favor conservative strategies, are no longer sufficient to meet the demands of precision medicine. To address this challenge, the Metastasis Lung Cancer Collaboration Group, Youth Specialists Committee of Beijing Medical Reward Foundation convened multidisciplinary experts from Medical Oncology, Radiology, Pathology, Radiotherapy, and Neurosurgery. Based on evidence-based medicine from the past decade and clinical practice experience, they have developed the Chinese expert consensus on clinical management of oncogene addicted NSCLC with leptomeningeal metastasis (2026 edition). This consensus emphasizes that the diagnosis of LM should be based on a comprehensive assessment of clinical symptoms, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) cytology. It also highlights the critical role of CSF molecular liquid biopsy in clarifying driver gene status and assessing treatment efficacy. In terms of treatment, this consensus advocates for a fundamental paradigm shift: therapy should be led by a multidisciplinary team (MDT), with high-CNS-penetration targeted therapies as the first-line intervention, while local treatments (such as intrathecal injection and radiotherapy) are positioned as supplementary measures. The consensus provides a series of expert recommendations on key aspects, including the selection of high-CNS-penetration tyrosine kinase inhibitors (TKIs), the application of intrathecal chemotherapy, the timing of radiotherapy, and palliative surgery. It aims to establish proactive, individualized treatment standards for patients with NSCLC LM in China, based on molecular subtyping and MDT collaboration, thereby improving patient survival outcomes.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance].","authors":"Sutong Zhan, Peilin Chen, Tangfeng Lv, Yong Song","doi":"10.3779/j.issn.1009-3419.2026.101.01","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.01","url":null,"abstract":"<p><p>Although targeted therapy has made significant advances in cancer treatment throughout these years, drug resistance still remains a major obstacle. Plenty of evidence has proved that abnormal expression of receptor tyrosine kinase AXL is associated with targeted therapy resistance and poor clinical outcomes. AXL drives drug resistance through diverse mechanisms, including altering tumor cell phenotypes, orchestrating DNA damage response process, promoting the activation of bypass signals, or interacting with other receptor tyrosine kinases. Preclinical and clinical studies have demonstrated that combined inhibition of AXL and the other target can enhance the efficacy of various targeted therapies and improve outcomes for patients with drug resistance. This review summarizes recent advances in the specific roles of AXL in targeted therapy resistance and AXL-targeted treatment strategies. It further explores the potential clinical value of combinatorial approaches involving AXL inhibition and discusses future directions for its application in developing novel targeted therapies and advancing precision oncology treatment. \u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"68-76"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}